Summary

AX200 was a novel and promising drug candidate with a comprehensive preclinical and clinical package that fulfilled Stroke Therapy Academic Industry Roundtable (STAIR) and European Stroke Organization recommendations; yet, no difference was observed in clinical outcome or imaging compared with placebo in acute ischemic stroke patients, according to results from the AX200 for the Treatment of Ischemic Stroke Phase 3 trial [AXIS-2; NCT00927836].